Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)
Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)
Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)
